Clark, Robert A.School of Medicine |
|
| 9/2012 - Present | Professor | UTHSCSA, Medicine, San Antonio, TX |
| 8/2006 - Present | Assistant Vice President for Clinical Research and Director, Institute for Integration of Medicine and Science | University of Texas Health Science Center at San Antonio, San Antonio, TX |
| 9/1994 - Present | Professor | University of Texas Health Science Center at San Antonio, Physiology, San Antonio, TX |
| 7/1994 - Present | Attending Physician | University Hospital, University Health System, San Antonio, TX |
| 7/1994 - Present | Staff Physician | South Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, TX |
| Year | Degree | Discipline | Institution |
| 1967 | MD | Medicine (Alpha Omega Alpha) | Columbia University, College of Physicians and Surgeons New York , NY |
| 1963 | AB | Mathematics (Magna Cum Laude) | Syracuse University Syracuse , NY |
| Residency | Resident in Medicine | Columbia Presbyterian Medical Center New York , NY |
|
| Residency | Chief Resident in Medicine | Harborview Medical Center Seattle , WA |
|
| Internship | Medicine | University of Washington Hospital Seattle , WA |
|
| Postdoctoral Fellowship | Infectious Diseases | Laboratory of Clinical Investigation, NIAID, NIH Bethesda , MD |
Biology of Aging- Basic research on biochemical and cellular pathways involved in the aging process. |
Calcium-Binding Proteins- Basic research on structure, function, and regulation of endoplasmic reticulum calcium-binding proteins. |
Infectious Diseases- Clinical infectious diseases. |
Inflammation- Basic research on mechanisms of the acute inflammatory response. |
Internal Medicine- Clinical general internal medicine. |
Neurodegenerative Disorders- Basic research on the biochemical and cellular pathways involved in neurodegenerative disorders, especially Parkinson's disease. |
Reactive Oxygen Species- Basic research on the mechanisms of generation of reactive oxygen species and their role in antimicrobial function, tissue injury, degenerative diseases, and aging. |
| Date | Description | Institution | # Students |
| 9/2012 - Present | Post-Doctoral Student Supervision | UTHSCSA | |
| 7/1994 - Present | Clin Infectious Disease | The University of Texas Health Science Center | 4 students |
Editorial |
| Clark RA. Hv1 H channel sustains neutrophil Nox2 activity, yet suppresses HOCl formation (in press) J Leuk Biol 2015 Jan;. |
Journal Article |
| He W, Jimenez F, Martinez H, Harper NL, Manoharan MS, Carillo A, Ingale P, Liu Y, Ahuja SS, Clark RA, Rather CG, Ramirez DA, Andrews CP, Jacobs RL, Ahuja SK. Cockroach sensitization mitigates allergic rhinoconjunctivitis symptom severity in patients allergic to house dust mites and pollen J Allergy Clin Immunol 2015 Sep;136(3):658-666. |
| Gornalusse G, Mummidi S, Gaitan AA, Jimenez F, Ramsuran V, Picton A, Rogers K, Manoharan M, Avadhanam N, Murthy KK, Martinez H, Molano Murillo AM, Chykarenko ZA, Hutt R, Daskalakis D, Shostakovich L, Karim SA, Martin JN, Deeks SJ, Hecht F, Sinclair E, Clark RA, Okulicz J, Valentine FT, Martinson N, Tiemessen CT, Ndung`u T, Hunt PW, He W, Ahuja SK. Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor Proc Natl Acad Sci (USA) 2015 Aug;112(34):E4762-E4771. |
| Okulicz JF, Le TD, Agan BK, Camargo JF, Landrum ML, Wright E, Dolan ML, Ganesan A, Ferguson TM, Smith DM, Richman DD, Little SL, Clark RA, He W, Ahuja SK. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals JAMA Internal Med 2015 Jan;175(1):88-99. |
| de Figueiredo ASP, Salmon A, Bruno F, Jimenez F, Martinez HG, Halade GV, Ahuja SS, Clark RA, DeFronzo RA, Abboud HE, El Jamali A. Nox2 mediates skeletal muscle insulin resistance induced by a high-fat diet J Biol Chem 2015 Jan;290(21):13427-13439. |
| Li G, Chen C, Liang S, Ballard C, Biju KC, Reddick RL, Clark RA, Li S. Hematopoietic knockdown of PPAR? reduces atherosclerosis in LDLR-/- mice (in press) Gene Therapy 2015 Jan;. |
| Valente AJ, Yoshida T, Clark RA, Delafontaine P, Siebenlist U, Chandrasekar B. Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling Free Radic Biol Med 2013 Jul;60:125-135. |
| Le TD, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, Young JA, Clark RA, Richman DD, Little SJ, Ahuja SK. Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy N Engl J Med 2013 Jan;368(3):218-230. |
| Biju KC, Santacruz R, Chen C, Zhou Q, Yao J, Rohrabaugh SL, Clark RA, Roberts JL, Phillips KA, Imam SZ, Li S. Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease Neurosci Letters 2013 Jan;535:24-29. |
| Imam SZ, Trickler W, Kimura S, Binienda ZK, Paule MG, Sikker W, Li S, Clark RA, Ali SF. Neuroprotective efficacy of a new brain-penetrating c-Abl inhibitor in a murine Parkinson?s disease model PLoS ONE 2013 Jan;8(5). |
Federal |
|
| Funding Agency | NIH/NHLBI |
| Title | Pathobiology of Occlusive Vascular Disease (Program Director - James Stockand) |
| Status | Active |
| Period | 9/2007 - 8/2022 |
| Role | Contributor |
| Grant Detail | This NIH training grant supports postdoctoral training in the area of occlusive cardiovascular disease, inflammation, and degenerative disorders of cardiovascular tissues. |
| Funding Agency | Veterans Health Administration |
| Title | Analysis of Olfactory Dysfunction for Early Diagnosis of Parkinson`s Disease |
| Status | Active |
| Period | 4/2016 - 3/2020 |
| Role | Principal Investigator |
| Grant Detail | This project will define the basis for olfactory dysfunction in early Parkinson?s disease in a genetic murine model employing expertise in olfaction, neurodegeneration, oxidative stress, neurobehavioral testing, and advanced imaging technologies. |
| Funding Agency | Department of Veterans Affairs |
| Title | Macrophage-Mediated Gene Delivery of Neurotrophic Factors for Parkinson`s Disease |
| Status | Active |
| Period | 10/2011 - 9/2019 |
| Role | Co-Investigator |
| Grant Detail | Using a chronic MPTP mouse model and regulatable glial-derived neurotrophic factor (GDNF)-expressing lentivectors, this project explores the efficacy and safety of hematopoietic stem cell-based macrophage-mediated GDNF gene therapy as a potential approach to Parkinson?s disease. |
| Funding Agency | NIH/NCATS |
| Title | Institute for Integration of Medicine & Science (IIMS): A Partnership to Improve Health (TL1 component of the Clinical and Translational Science Award) |
| Status | Active |
| Period | 5/2013 - 4/2018 |
| Role | Principal Investigator |
| Grant Detail | This institutional research training award represents the TL1 component of the Clinical and Translational Science Award. The goal is to support the research training of promising graduate students working in areas of translational science. I serve as the overall PI of the CTSA. My effort on the TL1 program is covered within the UL1 award. |
| Funding Agency | NIH/NIA |
| Title | Training Grant on the Biology of Aging (Program Director - Nicolas Musi) |
| Status | Active |
| Period | 5/1998 - 4/2018 |
| Role | Contributor |
| Grant Detail | This grant supports training for post-doctoral fellows in the basic biology of aging. |
| Funding Agency | NIH/NCATS |
| Title | Institute for Integration of Medicine & Science: A Partnership to Improve Health (Clinical and Translational Science Award) |
| Status | Active |
| Period | 5/2013 - 4/2018 |
| Role | Principal Investigator |
| Grant Detail | This Clinical and Translational Science Award (CTSA) provides a broad range of infrastructure support across the institution and its CTSA partners. This UL1 component provides all CTSA support except for the KL2 Career Development Award and TL1 Training Award, which are listed separately. I served as the NIH Contact PI and Director of the IIMS. Note that this 2013-2018 CTSA comprises a new award (with a different grant number) from the 2008-2013 CTSA, due to a change in the NIH sponsoring center from NCRR to NCATS. Also note that due to NIH delays the period from 05/2013 to 09/2013 was funded by an extension of the prior award, but for consistency those funds are included in the first year amount reported here. |
| Funding Agency | NIH/NCATS |
| Title | Institute for Integration of Medicine & Science (IIMS): A Partnership to Improve Health (KL2 Mentored Career Development component of the Clinical and Translational Science Award) |
| Status | Active |
| Period | 5/2013 - 4/2018 |
| Role | Principal Investigator |
| Grant Detail | This institutional research career development award represents the KL2 component of the Clinical and Translational Science Award. The goal is to support the career development of promising young clinical and translational investigators. I serve as the overall PI of the CTSA. My effort on the KL2 program is covered within the UL1 award. |
| Funding Agency | Veterans Health Administration |
| Title | Center for Personalized Medicine |
| Status | Active |
| Period | 4/2014 - 3/2018 |
| Role | Co-Principal Investigator |
| Grant Detail | This Program Project Grant (Program Director - Sunil K. Ahuja) supports three thematic projects and a core for carrying out research on the pathogenesis of HIV/AIDS, with an emphasis on host genetic and epigenetic determinants of susceptibility, disease progression, and response to therapy. |
Private |
|
| Funding Agency | William & Ella Owens Medical Research Foundation |
| Title | Methylene Bliue: A Novel Disease-Modifying Drug for Early Intervention in Parkinson`s Disease |
| Status | Active |
| Period | 1/2016 - 12/2016 |
| Role | Principal Investigator |
| Grant Detail | This project assesses the potential therapeutic benefits of methylene blue in murine models of Parkinson?s disease, employing genetic, neurobehavioral, and advanced imaging technologies. |